Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Biocon Biologics Limited
483
•Biocon Biologics Limited•July 26, 2024

Biocon Biologics Limited – FDA 483, Jul 26, 2024

Record Details

During an inspection conducted from July 15-26, 2024, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Biocon Biologics Limited, a drug substance and drug product manufacturer located in Bengaluru, India. The inspection revealed ten significant observations concerning compliance with Current Good Manufacturing Practice (cGMP) regulations.

Key issues included critical deficiencies in aseptic processing validation, where airflow visualization studies for sterile filling lines did not meet acceptance criteria or established protocols, leading to potential contamination risks. Furthermore, operators were observed failing to adhere to aseptic procedures, such as improper hand sanitization, unauthorized crossings of critical areas, and incorrect handling of sterile materials.

The FDA also noted significant lapses in laboratory controls, including the unauthorized reprocessing of chromatograms to alter Out-of-Specification results, inconsistent application of system suitability criteria, and the frequent use of manual data integration without proper justification. Data integrity was compromised by unreported failing non-viable particle count data, overwritten electronic records, and inadequate audit trail reviews for computerized systems.

Other observations highlighted insufficient investigations into deviations, recurring equipment malfunctions, inadequate environmental monitoring, and flawed disinfection practices. The firm lacked robust procedures for identifying particulate sources and faced issues with illegible labeling of cGMP materials. Biocon Biologics Limited is required to respond to these observations with a comprehensive plan of corrective and preventive actions to ensure product quality and patient safety.

Company
Biocon Biologics Limited
Inspection date
July 26, 2024
Product type
biologics
Office
Office of Compliance Intervention and Consultation
People
  • Teresa I. Navas
  • Justin A. Boyd (Research Specialist II)
  • Xiaoshi Wang
  • Richard Ledwidge
View Company Profile

ID · edb15a2b-be4c-4cce-a170-6454059f2901

Other documents for Biocon Biologics Limited
  • 483 - 2026-04-29April 29, 2026
  • 483 - 2022-08-26August 26, 2022
  • 483 - 2022-08-19August 19, 2022
  • 483 - 2019-09-19September 19, 2019
  • 483 - 2019-02-15February 15, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Biocon Biologics Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.